Correlation between median duration of response to first ADT or median TTCRPC and the outcome of patients treated with AA was analyzed. From January 2015 to November 2015, data of 59 patients with mCRPC were collected. We observed no differences in patient's median progression-free survival (PFS) and biochemical progression-free survival (bPFS), according to both median duration of response to first-line ADT (duration of first ADT < 13 months: median PFS and bPFS were 11 and 5 months, respectively; duration of ADT ≥ 13 months: median PFS and bPFS were 9 and 6 months, respectively) and median TTCRPC (TTCRPC < 28 months: median PFS and bPFS were 8 and 5 months, respectively; TTCRPC ≥ 28 months: median PFS and bPFS were 10 and 9 months, respectively). Overall survival, in the same group, did not differ between patients with a duration of response to first ADT over or under 13 months (P = 0.90) but in patients with a TTCRPC of 28 months or more, there was a trend toward longer survival than patients with TTCRPC less than 28 months (5-year overall survival was 74 vs. 50%; P = 0.14). The duration of response to first-line ADT and the TTCRPC showed no significant association with outcome of AA therapy in patients with mCRPC. However, large prospective trials are desirable to confirm these data. AntiCancer Drugs 28:110-115 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Prostate cancer is the most frequently diagnosed cancer in men in the Western World, and with an estimated 27 540 deaths in 2015 it represents the second leading cause of cancer-related deaths in men [1] . In 1972, Huggins and Hodges [2] showed that the proliferation and survival of prostate cancer cells critically depend on their stimulation by testosterone and dihydrotestosterone, through the binding of these hormones to the androgen receptor (AR), its subsequent translocation into the cell nucleus, and its binding to androgen-responsive elements of DNA. Despite initial success of the androgen deprivation therapy (ADT), almost all patients progress over a period of 18-24 months to a more aggressive and lethal stage of disease, known as castration-resistant prostate cancer (CRPC) [3] . It could be considered as a continuum of disease, ranging from patients without metastases or symptoms with rising prostate-specific antigen (PSA) levels despite ADT, to patients with metastases and significant disability, due to cancer symptoms [4] . AR signaling is thought to be crucial in CRPC as well, and this explains how therapies targeting the AR pathway [i.e. abiraterone acetate (AA) and enzalutamide (ENZ)] are also effective in advanced stage of disease [5] [6] [7] . Nevertheless, we learn from pivotal studies that forms of primary and acquired resistance to these drugs exist. In chemonaive and postdocetaxel patients who received AA for their CRPC, ∼ 5 and 35%, respectively, showed radiographic progression and PSA progression within 3 months [8] . In addition to novel antihormonal therapies, classic cytotoxic drugs such as docetaxel [9, 10] and cabazitaxel [11] contribute to expand metastatic CRPC therapeutic armamentarium, which also includes the bone-targeting radium-223 [12] . Because of the availability in the same therapeutic context of several safe and effective drugs and the existence of resistant forms of metastatic castration resistance prostate cancer (mCRPC) to these molecules, the identification of predictive factors for patient selection becomes crucial. Biomarkers could help clinician to develop the better sequence of therapy and to optimize cost-effective ratio for each patient. However, few data are available on ready-to-use clinical predictors of response to post-ADT drugs, and hence all approved therapies for the treatment of mCRPC were developed in unselected population [8] . Potential predictive biomarkers of response to docetaxel (i.e. MIC1 and AGR2) [13, 14] and novel hormonal agents (i.e. AR-V7 splice variant) [15, 16] have been identified but are not yet validated. In this scenario, clinical features and disease characteristics may still be of value in selecting patients for different treatments. For this reason, we reviewed data of 59 patients with mCRPC treated with AA at two Italian cancer centers, to assess whether or not a correlation between duration of response to first ADT, time to castration-resistant prostate cancer (TTCRPC), and outcome of AA therapy exists.
Patients and methods

Patients
We retrospectively analyzed data of mCRPC patients treated with AA, post-ADT, from November 2011 to November 2015 at two Italian cancer centers, the Sant'Andrea Hospital and the Regina Elena National Cancer Institute of Rome. CRPC was defined as a disease that progresses on ADT despite castrate serum testosterone levels (< 50 ng/ml) and may present as either a continuous rise in serum PSA levels, progression of preexisting disease, and/or the appearance of new metastases. The evaluated eligibility criteria were as follows: mCRPC confirmed by bone scan, computed tomography, or MRI, and treatment with AA as first-line, second-line, or third-line therapy. Duration of response to first ADT was defined as time between the start date of first hormonal therapy [HT, with luteinizing hormone-releasing hormone (LHRH) analog, antiandrogen, or both] and the first evidence of disease progression (biochemical and/or radiological). We measured the TTCRPC from the start of the ADT until the onset of the castration resistance.
Only patients for whom duration of response to the first ADT and TTCRPC were exactly measurable were included. Disease progression on AA therapy was defined as the variable combination of two of the following: biochemical, clinical, and radiological progression according to Prostate Cancer Working Group 2 criteria and RECIST 1.1 criteria.
Data collection
Data for the analysis included the following: metastatic sites (skeletal, nodal, or visceral metastasis), number of bone metastasis (< or ≥ 3), type of ADT (LHRH analog, antiandrogen, and complete androgen blockade), duration of first ADT, TTCRPC, type of progression on ADT (biochemical and/or radiological), total number of previous hormonal manipulations, PSA value, Gleason score, age and TNM at diagnosis, prior prostatectomy, local radiotherapy for prostate cancer, and line of treatment with AA.
Statistical analysis
The Kaplan-Meier method and Cox proportional hazard model were used to analyze survival data. Correlation between median duration of response to first ADT or the median TTCRPC and outcome of patient treated with AA was analyzed. Outcome assessments included the following: progression-free survival (PFS), biochemical progression-free survival (bPFS), and overall survival (OS). Number of subsequent hormonal manipulation was also considered. PFS was defined as the interval from start of AA therapy until disease progression or diseaserelated death. Data of patients still on treatment at the time of last visit were censored. The bPFS was defined as the interval from AA initiation until the first occurrence of PSA progression. OS was calculated from AA initiation until disease-related death (or censored at the date of last follow-up visit). Data of patients who died of other causes were censored.
Results
Clinical features
From January 2015 to November 2015 (date of last follow-up), data of 59 patients with mCRPC were collected. Demographic and disease features are summarized in Table 1 . The median age at diagnosis was 66 years (range 55-88 years). Median PSA before the start of ADT was 24.2 ng/ml (range 4.5-1680 ng/ml). Six (10%) patients had started ADT as adjuvant treatment, five (8%) patients for local recurrent disease, 14 (24%) patients for biochemical failure, and 29 (49%) patients for distant recurrence of disease. The median duration of first ADT and median TTCRPC was 13 and 28 months, respectively. Thirteen (22%), 11 (19%) , and 35 (59%) patients received LHRH analog, antiandrogen, or complete androgen blockade as first-line ADT, respectively. AA was administered as first-line, second-line, or third-line therapy for mCRPC in 13 (22%), 26 (44%), and 20 (34%) cases, respectively.
Other clinicopathological features are summarized in Table 1 .
Outcome of therapy with abiraterone acetate
We observed no differences in median PFS and bPFS of patients treated with AA, according to both median duration of response to first-line ADT [duration of first ADT < 13 months: median PFS 11 months; 95% confidence interval (CI):4-25 months; median bPFS 5 months, 95% CI: 4-17 months; duration of ADT ≥ 13 months: median PFS 9 months, 95% CI: 4-18 months; median bPFS 6 months, 95% CI: 3-13 months] and median TTCRPC (TTCRPC < 28 months: PFS 8 months, 95%
CI: 4-NA; bPFS 5 months, 95% CI: 3-9 months; TTCRPC ≥ 28 months: PFS 10 months, 95% CI: 5-21; bPFS 9 months, 95% CI: 5-24 months).
Moreover, OS in the same group did not differ between patients who responded to first ADT over or under 13 months (P = 0.90; Fig. 1 ) but in patients with a median TTCRPC of 28 months or more, OS was longer than that in patients with TTCRPC less than 28 months, but the difference was not statistically significant (5-year OS was 74 vs. 50%; P = 0.14; Fig. 1 ).
Discussion
In the phase III study COU-AA-301 median duration of exposure to gonadotropin release hormone analog (GnRHa) and AR antagonist was 45 and 15.7 months, respectively [17] . If we consider the group of patients included in our study most similar to the population of the pivotal study (TTCRPC ≥ 28 months) the efficacy results of our study are comparable in terms of bPFS (9 vs. 8.5 months) to those reported in the phase III trial. However, the median PFS observed in the same group was longer than that in the trial cohort (10 vs.
months).
The results from our retrospective analysis suggest that PFS and bPFS do not seem to be influenced by duration of response to first-line ADT and TTCRPC in patients treated with AA for mCRPC. In our opinion, although the duration of response to first-line ADT could outline cancer hormone sensitivity and response, the TTCRPC could better represent the total period of patient's exposition to endocrine therapy (linked also to the numbers of hormonal manipulations). Patients who rapidly progressed (< 13 months) on first ADT did not show inferior OS, PFS, and bPFS on AA therapy compared with long responders (≥13 months). In our study, even stratification with TTCRPC did not yield statistically significant differences for PFS and bPFS. These findings are consistent with that reported by Bellmunt et al. [17] in their post-hoc exploratory analysis on COU-AA-301 and COU-AA-302 populations (1195 and 1088 patients, respectively). In this study, the authors tried to establish whether the duration in quartiles (Q1 < 20 months, 21 ≤ Q2 < 37 months; 38 < Q3 ≤ 61 months; Q4 > 61 months) of prior treatment with GnRHa or AR antagonist could have effect on the AA outcome [OS, radiographic progression-free survival (rPFS), and PSA response]. They showed that, in both trials, OS, rPFS, and PSA response were improved in the AA group versus the placebo group, in all quartiles of duration of prior endocrine therapy, suggesting that the benefit of AA was maintained, regardless of the type and duration of prior ADT. They also observed that a longer exposure on prior endocrine therapy in COU-AA-301 and COU-AA-302 was associated with a longer time-to-death and rPFS regardless of treatment assignment. Similarly, as a result of their exploratory analysis on COU-AA-302 trial population (1088 patients), Oudard et al. [18] suggested that duration of prior endocrine therapy (below/above median duration: 37 months for GnRHa, 16 months for antiandrogen) did not affect the clinical benefit of AA.
Conversely, the retrospective analysis conducted by Loriot et al. [19] on 173 patients suffering from mCRPC and treated with AR-axis-targeted drugs (ENZ, n = 57; antiandrogen, n = 47; abiraterone, n = 17; others, n = 54) revealed that, in long responders to initial ADT (>12 months), the median PFS was 3 months longer than that in short responders (2.8 vs. 5.8 months; hazard ratio 0.58; P = 0.002). Moreover, Angelergues and colleagues confirmed in 132 men with mCRPC that an early-onset CRPC (< 12 months) during first HT was associated with a poor prognosis and a low response to second hormonal manipulations. Moreover, they have shown no difference in PSA response to taxanes correlated with the duration of first ADT, but observed a shorter time to biochemical progression in men with TTCRPC less than 12 months [20] . Finally, Hung and colleagues showed that patients with a rapid castration resistance (< 1 year) had inferior PFS and OS on AA and ENZ therapy compared with long responders to ADT (≥1 year). Nevertheless, duration of response to castration therapy when combined with other clinical variables has not been confirmed as an independent predictor of AA and ENZ response [21] .
However, our data have showed that a later castration resistance onset (TTCRPC ≥ 28 months) was associated with a better 5-year OS (74 vs. 50%; P = 0.14), which is in accordance with that showed by others. In 2013, Halabi et al. [22] developed and validated a prognostic model for mCRPC patients who progressed after a first-line therapy with docetaxel. This is the first prognostic model that included the 'duration of HT' as well as 'time since docetaxel use' in mCRPC patients treated with mitoxantrone + prednisone or cabazitaxel + prednisone (according to randomization) as second-line treatment. Finally, Afshar et al. [23] identified duration of response to ADT as an independent predictors of OS in 61 CRPC patients treated with AA as second-line therapy.
Moreover, Chi et al. [24] explored the potential prognostic role in mCRPC of previous ADT in 2013. They analyzed data from 729 patients treated with AA in the ADT, androgen deprivation therapy; bPFS, biochemical progression-free survival; CRPC, castration-resistant prostate cancer; DES, diethylstilboestrol; GnRH, gonadotrophin-releasing hormone; HR, hazard ratio; HT, hormonal therapy; LHRH, luteinizing hormone-releasing hormone; OS, overall survival; PFS, progression-free survival; rPFS, radiographic progression-free survival; TTBP, time to biochemical progression; TTCRPC, time to castrationresistant prostate cancer.
COU-AA-301 study and showed that an interval from the beginning of LHRH agonist therapy until the starting of second-line therapy with AA of 36 months or more was associated with a poor prognosis (hazard ratio = 1.30; P = 0.0078). Thus, our results are consistent with that shown by others in terms of the prognostic value of duration of HT in prostate cancer ( Table 2 ).
The present study has important limitations such as a small sample size and the retrospective nature. Therefore, large prospective trials are necessary to confirm these data.
Conclusion
According to findings from other studies, our results highlight that the efficacy of AA treatment in patients with mCRPC is not influenced by duration of response to first-line ADT and TTCRPC. However, a longer exposure to ADT seems to predict a better OS in patients treated with AA. Large prospective trials are needed to confirm these data.
